DTL
TPST icon

Dynamic Technology Lab’s Tempest Therapeutics TPST Stock Holding History

Dynamic Technology Lab’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13
Closed -$56K – 1272
2016
Q4 		$56K Buy
+13
New +$162K 0.02% 834

Other funds holding TPST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Dynamic Technology Lab's TPST Position: Q1 2017 in Review

Dynamic Technology Lab sold out of Tempest Therapeutics (TPST) in Q1 2017, closing a stake of 13 shares — an estimated $56K sold.

Dynamic Technology Lab first reported a position in TPST in Q4 2016 and held it in 1 quarter. The position peaked at $56K in Q4 2016. 63 funds tracked by Wall St. Rank hold TPST as of Q1 2017.

  • Dynamic Technology Lab reported no remaining Tempest Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Dynamic Technology Lab sold 13 Tempest Therapeutics shares in Q1 2017, an estimated $56K.
  • Dynamic Technology Lab first reported a position in Tempest Therapeutics in Q4 2016 and held it in 1 quarter.
  • Dynamic Technology Lab's Tempest Therapeutics position peaked at $56K in Q4 2016.
  • 63 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2017.

Based on Dynamic Technology Lab's 13F filing for Q1 2017, filed 11 May 2017.